Aprea Therapeutics, Inc. (APRE) Stock Ticker
Market factors today
Unlock the full APRE picture
About Aprea Therapeutics, Inc.
Aprea Therapeutics, Inc. is a biopharmaceutical company in its clinical development stage, dedicated to discovering and marketing innovative cancer treatments. Their therapeutic approach centers on modulating DNA damage response pathways. The company's primary drug candidate, ATRN-119, is an oral ATR inhibitor currently undergoing Phase 1/2a clinical trials for patients with advanced solid tumors. Beyond this lead compound, Aprea's developmental pipeline includes ATRN-Backup, which is also an ATR inhibitor; ATRN-W1051, being explored for its anti-tumor effects; and ATRN-DDRi. Aprea Therapeutics, Inc. is headquartered in Boston, Massachusetts.
APRE stock facts
| Ticker symbol | APRE |
| Exchange | NASDAQ Global Select |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $9.4M |
| CEO | Oren Gilad |
| Employees | 8 |
| Headquarters | Boston, PA, US |
| IPO date | 2019-10-03 |
| Website | www.aprea.com |
What you can see for APRE on Tickr
Live APRE price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the APRE report.
Rankings
FAQ
What is the ticker symbol for Aprea Therapeutics, Inc.?
The ticker symbol for Aprea Therapeutics, Inc. is APRE, listed on the NASDAQ Global Select.
What is APRE?
Aprea Therapeutics, Inc. is a biopharmaceutical company in its clinical development stage, dedicated to discovering and marketing innovative cancer treatments. Their therapeutic approach centers on modulating DNA damage response pathways. The company's primary drug candidate, ATRN-119, is an oral ATR inhibitor currently undergoing Phase 1/2a clinical trials for patients with advanced solid…